Imp. paper by @VincentRK ๐๐ก ๐๐ on mode of progression in a ๐ฆ๐จ๐๐๐ซ๐ง ๐๐จ๐ก๐จ๐ซ๐ญ of patients with smoldering #myeloma!
Helpful for initial discussion in patients with ๐๐ข๐ ๐ก-๐๐ข๐ฌ๐ค ๐๐๐ re. clinical trials vs active surveillance vs Len
1/4 tinyurl.com/4w4bmzen
Helpful for initial discussion in patients with ๐๐ข๐ ๐ก-๐๐ข๐ฌ๐ค ๐๐๐ re. clinical trials vs active surveillance vs Len
1/4 tinyurl.com/4w4bmzen
๐finding: 23/71 pts. (~๐๐%) with HR-SMM progressed to clinically significant MDEs (Bone Disease/Hypercalcemia/Renal Failure) at a median f/u of ~4 years!
In other words, >2/3rd of patients with HR-SMM did ๐ง๐จ๐ญ have clinically significant MDEs at progression!
2/4
In other words, >2/3rd of patients with HR-SMM did ๐ง๐จ๐ญ have clinically significant MDEs at progression!
2/4
What about all MDEs (CRAB)?
At a median follow-up of ~4 years, 39/71 patients (~๐๐%) with HR-SMM on active surveillance progressed to CRAB! This is ๐ฌ๐ฎ๐๐ฌ๐ญ๐๐ง๐ญ๐ข๐๐ฅ๐ฅ๐ฒ ๐ฅ๐จ๐ฐ๐๐ซ than 2-year risk of ~50% in pts with HR-SMM, as we quote using 20/2/20!
3/4
At a median follow-up of ~4 years, 39/71 patients (~๐๐%) with HR-SMM on active surveillance progressed to CRAB! This is ๐ฌ๐ฎ๐๐ฌ๐ญ๐๐ง๐ญ๐ข๐๐ฅ๐ฅ๐ฒ ๐ฅ๐จ๐ฐ๐๐ซ than 2-year risk of ~50% in pts with HR-SMM, as we quote using 20/2/20!
3/4
Imp.โ: What % of pts had baseline ๐๐ ๐๐-๐๐๐, the most sensitive imaging modality to r/o myeloma? Its plausible that with WB DW-MRI, fewer bone lesions may be expected as MDEs!
Grateful to the ๐๐พdatabase @MayoMyeloma that has taught us so much about this disease!
4/4
Grateful to the ๐๐พdatabase @MayoMyeloma that has taught us so much about this disease!
4/4
Curious to hear thoughts from SMM aficionados @EliasKarlMai @ManniMD1 @arjunlakshmanMD @SusanBal9 @MeeraMohanMD @AaronGoodman33 @MalinHultcrantz @Amyloid_Planet
โข โข โข
Missing some Tweet in this thread? You can try to
force a refresh
ใ
